NCT06114251View on ClinicalTrials.gov

Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

920

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

June 1, 2023

Conditions
Liver Transplant; Complications
Interventions
DIAGNOSTIC_TEST

Diagnosis of postoperative recurrence of liver cancer

HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT06114251 - Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter